Related Experiment Video

Updated: Jun 7, 2025

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

6.7K

IRAK2 overexpression restrains prostate cancer progression by regulation of TRAF6 ubiquitination

Yunfeng Shi1, Chengshuai Wu1, Chengyue Wang1

  • 1Urology Surgery, Wujin Hospital Affiliated with Jiangsu University, The Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu Province, China.

Cellular Signalling
|November 16, 2024
PubMed

Insights

Interleukin-1 receptor-associated kinase 2 (IRAK2) acts as a tumor suppressor in prostate cancer. Upregulating IRAK2 inhibits cancer progression and enhances docetaxel sensitivity, suggesting it as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Prostate cancer is a prevalent malignancy globally, with incomplete understanding of its molecular drivers.
  • Identifying novel molecular mechanisms is crucial for developing effective prostate cancer therapies.

Purpose of the Study:

  • To investigate the role of interleukin-1 receptor-associated kinase 2 (IRAK2) in prostate cancer progression.
  • To explore IRAK2's potential as a therapeutic target for prostate cancer.

Main Methods:

  • Analysis of IRAK2 expression in prostate cancer tissues and cells.
  • Functional studies including MTT, transwell, wound healing, and xenograft assays.
  • Investigation of IRAK2's interaction with TNF receptor-associated factor 6 (TRAF6) and its effect on TRAF6 ubiquitination and degradation.
  • Assessment of IRAK2's influence on docetaxel (DTX) sensitivity.

Main Results:

  • IRAK2 expression is downregulated in prostate cancer.
  • IRAK2 upregulation suppressed prostate cancer cell viability, migration, invasion, and tumor growth.
  • IRAK2 interacts with TRAF6, inhibiting its ubiquitination and degradation, thereby suppressing cancer progression.
  • IRAK2 overexpression enhanced prostate cancer cell sensitivity to docetaxel.

Conclusions:

  • IRAK2 functions as a tumor suppressor in prostate cancer.
  • IRAK2 represents a potential therapeutic target for prostate cancer treatment.
  • Targeting IRAK2 may improve the efficacy of chemotherapy, such as docetaxel.
Keywords:
IRAK2Prostate cancerTRAF6Tumor progressionUbiquitination

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

963
Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration10:43

Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration

Published on: May 19, 2016

6.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K